Merck $95 million acquisition of cCam Biotherapeutics

29/8/2015
Public acquisition

$ 95 million

Completed

29/8/2015


Overview:

  • Merck has acquired cCam Biotherapeutics for an initial $95 million.
  • The deal also includes a potential $510 million in performance payments.
  • cCam Biotherapeutics is an Israeli biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.

Sam Duke - Editor

Jurisdiction:

Israel

Deal type:

Public acquisition

Practice area:

M&A

Industry sectors:

Healthcare
Pharmaceuticals and life sciences


Firms:

Party: cCam Biotherapeutics (Target)

Lawyer: Yuval Horn


Party: Merck (Acquirer)

Lawyer: Clifford Felig


Party: cCam Biotherapeutics (Target)


Party: OrbiMed (Seller, Shareholder)

Lawyer: Barry Levenfeld